🇺🇸 FDA
Patent

US 10774056

Substituted piperazines as selective HDAC1,2 inhibitors

granted A61PA61P35/00A61P35/02

Quick answer

US patent 10774056 (Substituted piperazines as selective HDAC1,2 inhibitors) held by Regenacy Pharmaceuticals, Inc. expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regenacy Pharmaceuticals, Inc.
Grant date
Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61P, A61P35/00, A61P35/02, A61P7/00